Price (delayed)
$2.08
Market cap
$6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$44.6
Enterprise value
$13.21M
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for
There are no recent dividends present for EYEN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.